No to 'ever-greening'
The Pharmaceutical Research and Manufacturers of America and the United States India Business Council are miffed over the recent Novartis judgment of the Supreme Court (SC) of India. For us, however,
Patent Rules 2005
-
Supreme Court judgement dated 01-04-2013:in Appeal Civil No. 2706-2716/2013 @ SLP(C) 20539-20549/2009 Novartis AG Vs. Union of India and ors (Patent/Cancer Drug)
Supreme Court judgement dated 01-04-2013:in Appeal Civil No. 2706-2716/2013 @ SLP(C) 20539-20549/2009 Novartis AG Vs. Union of India and ors (Patent/Cancer Drug).
-
The compulsory licence for Nexavar - A landmark order
The compulsory licence issued to Natco for manufacture of the anti-cancer drug Nexavar is a landmark decision on many grounds – the first one in India since the 2005 amendment to the 1970 Patents Act and
-
Compulsory licensing of pharmaceutical patents
It is scandalous that India is yet to issue a single compulsory licence for a drug after the 2005 amendment. (Editorial)
-
Advantage MNCs: Govt wont tweak drug patent rules
Khomba Singh & Sushmi Dey NEW DELHI THE commerce ministry
-
Microbes can be patented
Mashelkar report says modified organisms are intellectual property THE expert group on patent law headed by R A Mashelkar has recommended that microbes like bacteria, fungi and virus should be patented if they have been modified. The committee has also said India cannot limit its patents to new chemical substances in pharmaceutical products. The recommendations were submitted to the Union
-
The value of incremental pharmaceutical innovation: benefits for Indian patients and Indian business
Improved quality of drug products in India, including products that are better suited to India
-
Trials and TRIPS-ulations: Indian patent law and Novartis ag v. Union of India
When pharmaceutical company Novartis challenged the rejection of its patent application for the leukemia drug Gleevec in Novartis AG v. Union of India, it became the first major legal challenge to India’s